SCHEMBL1608290

SCHEMBL1608290

NC(=O)/C=C\c1ccccc1O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NFKB1 P19838 2/20 0.70
JUN P05412 1/20 0.70
NFE2L2 Q16236 1/20 0.70
CA1 P00915 1/20 0.68
CA2 P00918 1/20 0.68
CA4 P22748 1/20 0.68
MAPT P10636 3/20 0.66
LMNA P02545 1/20 0.66
BCHE P06276 1/20 0.61
GUSB P08236 1/20 0.61
CHRNA7 P36544 3/20 0.56
MAPK1 P28482 2/20 0.54
CDK4 P11802 1/20 0.53
CCND1 P24385 1/20 0.53
ALPL P05186 1/20 0.53
ALPI P09923 1/20 0.53
ALPG P10696 1/20 0.53
KDM4E B2RXH2 1/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8687395 1.00 NFKB1 (0.70) NFKB1JUNNFE2L2CA1CA2
SCHEMBL29625452 1.00 NFKB1 (0.70) NFKB1JUNNFE2L2CA1CA2
SCHEMBL765999 1.00 NFKB1 (0.70) NFKB1JUNNFE2L2CA1CA2
SCHEMBL766000 1.00 NFKB1 (0.70) NFKB1JUNNFE2L2CA1CA2
SCHEMBL11406934 0.98 NFKB1 (0.68) NFKB1JUNNFE2L2CA1CA2
SCHEMBL2328371 0.87 NFKB1 (0.50) NFKB1JUNNFE2L2CA1CA2
SCHEMBL5465666 0.84 IAPP (0.68) NFKB1JUNNFE2L2CA1CA2
SCHEMBL1160535 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
SCHEMBL29539991 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2
SCHEMBL1160537 0.83 NFKB1 (1.00) NFKB1JUNNFE2L2CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113402491-A Coumarin amide compound and preparation method and application thereof 山东大学苏州研究院 2021-09-17 CN claimed
CN-107935976-B Coumarin amide derivative and application thereof 山东大学 2020-01-17 CN claimed
EP-4737505-A1 RESIN, PHOTOSENSITIVE COMPOSITIONS, CURED OBJECT, DISPLAY DEVICE, ELECTRONIC COMPONENT, AND METHOD FOR PRODUCING CURED OBJECT Toray Industries, Inc. (JP) 2026-05-06 EP disclosed
US-20260079397-A1 PHOTOSENSITIVE COMPOSITION, CURED PRODUCT, ELECTRONIC COMPONENT, AND METHOD FOR PRODUCING CURED PRODUCT TORAY INDUSTRIES, INC. (JP) 2026-03-19 US disclosed
CN-117362259-B 6-Azo phenyl coumarin-3-formamide compound, and preparation method and application thereof 南京林业大学 2025-08-08 CN disclosed
EP-4597224-A1 PHOTOSENSITIVE COMPOSITION, CURED PRODUCT, ELECTRONIC COMPONENT, AND METHOD FOR PRODUCING CURED PRODUCT Toray Industries, Inc. (JP) 2025-08-06 EP disclosed
CN-120078865-A Medicinal tea composition, medicinal tea liquid and application thereof 新疆和田学院 2025-06-03 CN disclosed
CN-119895333-A Photosensitive composition, cured product, electronic component, and method for producing cured product 东丽株式会社 2025-04-25 CN disclosed
CN-117777114-A Large Stokes displacement near-infrared cell membrane targeting dye based on coumarin skeleton and preparation method and application thereof 西藏自治区人民政府驻成都办事处医院 2024-03-29 CN disclosed
CN-117362259-A 6-azo phenyl coumarin-3-formamide compound, and preparation method and application thereof 南京林业大学 2024-01-09 CN disclosed
CN-116947796-A Method for synthesizing coumarin-3-carboxylic ester 常州大学 2023-10-27 CN disclosed
WO-2006050501-A2 NOVOBIOCIN ANALOGUES AS ANTICANCER AGENTS UNIVERSITY OF KANSAS (US) 2006-05-11 WO disclosed
US-6852310-B2 Skin lightening agents, compositions and methods UNILEVER HOME & PERSONAL CARE USA DIVISION OF CONOPCO, INC. (US) 2005-02-08 US disclosed
CN-1506359-A Coumarin amide derivative and its prepn, medicinal composition and use �й�ҽѧ��ѧԺҩ���о��� 2004-06-23 CN disclosed
WO-2004017936-A1 SKIN LIGHTENING AGENTS COMPRISING COUMARIN DERIVED FROM RESORCINOL DERIVATIVES UNILEVER PLC (GB) 2004-03-04 WO disclosed
US-20040042983-A1 Skin lightening agents, compositions and methods UNILEVER HOME & PERSONAL CARE USA, DIVISION OF CONOPCO, INC. 2004-03-04 US disclosed
EP-0869785-B1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF NON-INSULIN DEPENDENT DIABETES MELLITUS UPJOHN CO (US) 2002-08-28 EP disclosed
EP-0869785-A1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS PHARMACIA & UPJOHN COMPANY (US) 1998-10-14 EP disclosed
US-5723476-A 4-hydroxycoumarin-3-carboxamides for the treatment of diabetes mellitus PHARMACIA & UPJOHN COMPANY (US) 1998-03-03 US disclosed
WO-1997018808-A1 4-HYDROXYCOUMARIN-3-CARBOXAMIDES FOR THE TREATMENT OF DIABETES MELLITUS PHARMACIA & UPJOHN COMPANY (US) 1997-05-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260079397-A1 PHOTOSENSITIVE COMPOSITION, CURED PRODUCT, ELECTRONIC COMPONENT, AND METHOD FOR PRODUCING CURED PRODUCT PPA1, PHOSPHO1, PHPT1 NFKB1 3988/4885JUN 4762/4885NFE2L2 2912/4885
US-20040042983-A1 Skin lightening agents, compositions and methods AOC3, TYR, CYP8B1 NFKB1 3030/4885JUN 2469/4885NFE2L2 531/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.